In a study of assessing the late distant recurrence risk in patients with hormone receptor-positive breast cancer showed that age, nodal involvement, tumor size and grade could be used to calculate a risk score, named as “Clinical Treatment Score Post 5 Years” [30]. This evidence concerns the gene NR4A1 and neoplasm.